Metabolic effects associated to the highly active antiretroviral therapy (HAART) in AIDS patients
AUTOR(ES)
Domingos, Hamilton, Cunha, Rivaldo Venâncio da, Paniago, Anamaria Mello Miranda, Martins, Diego Mira, Elkhoury, Eduardo Brandão, Souza, Albert Schiaveto de
FONTE
Brazilian Journal of Infectious Diseases
DATA DE PUBLICAÇÃO
2009-04
RESUMO
The aim of this study was to evaluate the metabolic abnormalities (dyslipidaemia and insulin resistance) associated with highly active antiretroviral therapy (HAART) in AIDS patients, treated in Campo Grande, Mato Grosso do Sul, Brazil. The patients were distributed in five different groups: Group 1, HIV-infected without antiretroviral therapy; Group 2, with Zidovudine, Lamivudine and Efavirenz or Nevirapine; Group 3, with Zidovudine, Lamivudine and Protease Inhibitor; Group 4, with Stavudine, Lamivudine and Efavirenz or Nevirapine; and Group 5, with Stavudine, Lamivudine and Protease Inhibitor. The lipid and glucose profile were determined and statistics comparison was made. The findings of this study showed significant statistics elevations of total cholesterol and triglycerides levels in patients of Groups 3, 4 and 5, when comparing to patients of Groups 1 and 2. Significant differences were not observed between the groups in the others parameters evaluated: Glucose, HDL cholesterol and LDL cholesterol. Comparing two drugs of same class (NNRTI) through the subgroups II-efavirenz and II-nevirapine, significant differences in the serum levels of total cholesterol, triglycerides and glucose favorable to the subgroup II-NVP were observed. These findings suggest that combinations including Protease Inhibitors and/or Stavudine could cause more adverse metabolic effects, and if possible, should be avoided in patients with others cardiovascular risk factors to prevent the precocious atherosclerosis in AIDS patients receiving HAART.
Documentos Relacionados
- Ocular problems in brazilian patients with AIDS before and in highly active antiretroviral therapy (HAART) era
- Effectiveness of highly active antiretroviral therapy (HAART) used concomitantly with rifampicin in patients with tuberculosis and AIDS
- Highly Active Antiretroviral Therapy (HAART) and Circulating Markers of Immune Activation: Specific Effect of HAART on Neopterin
- Risk factors for cardiovascular disease in HIV/AIDS patients treated with highly active antiretroviral therapy (HAART) in the central-southern region of the state of Paraná – Brazil
- Dyslipidemia in AIDS patients on highly active antiretroviral therapy